Literature DB >> 136342

Subcutaneous, isogeneic transplantation of either duct-ligated pancreas or isolated islets in streptozotocin diabetic mice.

R C Kramp, R Cuche, A E Renold.   

Abstract

Recovery from hyperglycemia was observed in streptozotocin diabetic mice that received subcutaneous, isogeneic transplants of either isolated islets or duct-ligated pancreas. Transplants of isolated islets obtained from collagenase-digested adult pancreas provided recovery from hyperglycemia, but the incidence of recovery depended on the amount of islet tissue initially transplanted. Hyperplastic, insulin-rich islets obtained from the pancreas of obese hyperglycemic mice (ob/ob) allowed recovery between 3 and 6 weeks, whereas an equivalent number of islets obtained from non-obese, normal donors gave only partial recovery after 8 weeks. Implantation of pancreatic endocrine tissue obtained from adult donors whose pancreatic ducts were ligated several weeks earlier, led to consistent recovery within 8 to 10 weeks. The content of immunoreactive insulin (IRI) extracted from transplants of mice recovering from hyperglycemia was 16 to 19% of that found in the normal mouse pancreas and was about 4 times greater than that remaining in the recepient's own pancreas. Transplants removed from hosts that did not recover contained a relatively small amount of IRI indicating that these transplants contained insufficient insulin stores to allow recovery form hyperglycemia.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 136342     DOI: 10.1210/endo-99-5-1161

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  2 in total

Review 1.  Pancreas and islet transplantation. I. Experimental studies.

Authors:  D E Sutherland
Journal:  Diabetologia       Date:  1981-03       Impact factor: 10.122

2.  Limitations of the pig-to-non-human primate islet transplantation model.

Authors:  Martin Wijkstrom; Rita Bottino; David K C Cooper
Journal:  Xenotransplantation       Date:  2013-01-09       Impact factor: 3.907

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.